We’re excited to announce that Biocytogen will be attending the ACT 46th Annual Meeting, taking place November 16–19 in Phoenix, Arizona! Join us as we engage with leading scientists from the pharmaceutical, biotechnology, consulting, and research sectors. This annual gathering brings together a dynamic community of toxicologists in a collaborative environment that promotes scientific exchange, professional networking, and continuing education. We look forward to connecting with you in Phoenix!
What is ACT 46th Annual Meeting?
The American College of Toxicology (ACT) will host its 46th Annual Meeting in Phoenix, Arizona, with the mission to “Educate, Lead, and Serve” scientists by fostering meaningful connections and the exchange of knowledge in applied toxicological sciences. This premier event will feature a robust lineup of scientific sessions, educational courses, keynote presentations, a poster session, an awards ceremony, and various networking opportunities. ACT Expo Live! and the Supporter Program provides valuable platforms for companies to engage with industry professionals and explore future developments and objectives within the field of toxicology.
Event Overview
Date: November 16th- 19th, 2025
Venue: JW Marriott Phoenix Desert Ridge Resort & Spa. 5350 E Marriott Dr, Phoenix, AZ
Event Schedule
For more information, please refer to the ACT Program.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We can’t wait to see you at the ACT Annual Meeting in Phoenix, Arizona !
